Shares of Regenxbio Inc (NASDAQ:RGNX) have earned a consensus recommendation of “Buy” from the eleven ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $87.83.
A number of brokerages have recently weighed in on RGNX. Morgan Stanley set a $84.00 target price on Regenxbio and gave the stock a “buy” rating in a research note on Monday, July 15th. BidaskClub downgraded Regenxbio from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Chardan Capital restated a “buy” rating and issued a $150.00 target price (up previously from $145.00) on shares of Regenxbio in a research note on Tuesday, June 18th. Raymond James started coverage on Regenxbio in a research note on Thursday, June 13th. They issued an “outperform” rating on the stock. Finally, Evercore ISI set a $79.00 price target on shares of Regenxbio and gave the stock a “buy” rating in a report on Wednesday, August 7th.
In other news, SVP Patrick J. Christmas sold 5,000 shares of the company’s stock in a transaction on Friday, July 19th. The shares were sold at an average price of $50.03, for a total value of $250,150.00. Following the transaction, the senior vice president now owns 3,058 shares of the company’s stock, valued at $152,991.74. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Kenneth T. Mills sold 15,000 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $42.99, for a total transaction of $644,850.00. Following the completion of the transaction, the insider now directly owns 261,000 shares in the company, valued at approximately $11,220,390. The disclosure for this sale can be found here. Insiders have sold a total of 73,000 shares of company stock worth $3,590,400 in the last three months. Insiders own 13.80% of the company’s stock.
Shares of RGNX opened at $37.45 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.58 and a current ratio of 14.58. The company has a 50-day moving average price of $46.33. The firm has a market cap of $1.45 billion, a P/E ratio of 15.74 and a beta of 0.71. Regenxbio has a one year low of $35.70 and a one year high of $83.45.
Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.46. Regenxbio had a negative return on equity of 15.39% and a negative net margin of 88.57%. The business had revenue of $7.88 million during the quarter, compared to the consensus estimate of $5.45 million. During the same quarter in the previous year, the business earned $0.30 EPS. The company’s quarterly revenue was down 80.3% on a year-over-year basis. Equities research analysts predict that Regenxbio will post -2.54 earnings per share for the current fiscal year.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Read More: Elliott Wave Theory
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.